Phase II Trial of Doxil, Carboplatin, Bevacizumab in Triple Negative Untreated Metastatic Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: Doxil|DRUG: Carboplatin|DRUG: Bevacizumab
Sponsor: Rutgers, The State University of New Jersey
Collaborators: Rutgers Cancer Institute of New Jersey|National Cancer Institute (NCI)